Chinese medicine White Horse Stock Giants encountered flash collapse?What's wrong with the stock price of a new year?

In the Chinese capital market, Pianzai has attracted much attention from the market as a few countries to protect Chinese medicine. However, in recently, this hot white horse stocks have encountered Waterloo. What happened to asking this puppet?

1. The Chinese Medicine White Horse Stock Giants encountered flash collapse?

According to Zhongxin Jingwei reports, recently, a "white horse stock" plummeted every day in the A -share market. First, "CXO Mao" Yao Ming Kangde, then "Medical Mei Mao" beauty guest, and then "Equipment Mao" Mai Rui Medical. On the 22nd, Zhangzhou Pianzi Pharmaceutical Co., Ltd. (hereinafter referred to as Pianzi), the "Mamutama Moutai" Zhangzhou Pharmaceutical Co., Ltd. (hereinafter referred to as Pianzi Tsai) fell sharply, with a closing of more than 7%. It is worth mentioning that the stock price of 259.69 yuan per share in the market today has reached a new low over the past year.

Regarding today's stock price plunge, an insident close to the company told Zhongxin Jingwei that everything was normal. Some experts believe that it is difficult to return to 200 billion yuan in market value in a short period of time.

Public information shows that Pianzai was founded by the former Zhangzhou Pharmaceutical Factory in December 1999. It is a time -honored enterprise in China. The main business includes Chinese medicine manufacturing and medical circulation. It was listed on the main board of Shanghai in 2003. Among them, the core products are Shiba Tsai series, including Pianzai, Shinzai Capsules, and compound Shinzi Mikai, etc.

In fact, the stock price of Pianzai has not been adjusted recently. Since the end of 2021, Pianzai's stock price has begun to fluctuate. Wind data shows that since this year, the stock price of Pianzi has fallen 40.11%, which has reached a new low of 259.69 yuan/share today. It is worth noting that from the end of 2021 to the first half of this year, the stock price of Pianzi showed a trend of shocking. However, during this time, some of the top ten shareholders of Pianzi were still "adding", and some had retreated.

2. What happened to the stock price of a new low year?

We see that the famous Chinese medicine Baima stocks have a significant decline in the stock price. Many people are asking what happened to Shi Tsai, causing such a large -scale decline in the stock price. What should the company think about the company?

First of all, from the perspective of market development, the current significant decline in pharmaceutical stocks is actually not a problem with the family of Pianzi, but the current large market is affected by the shock, especially the influence of some serious watching emotions. A large number of pharmaceutical stocks are actually actual. There are relatively large market pressure on the top. Not only are the puppets, but many companies have more or less problems. In addition, we can also observe the investment value of Pianzai. In these years, it has been in a state of overestimation. Under such overall valuations, the overall stock price of Pianzi 癀 is relatively high. Therefore, we have observed that the stock price has been adjusted since the end of last year. This process has always been going to the bubble state, and in this downward passage, the market value of Shiba 癀 will return to the previous 20 billion yuan of the previous 20 billion yuan. High -level is actually relatively difficult.

Secondly, what we see is that the current Pianzai is not only a large number of shareholders who are more worried about its development. Many major shareholders of Pianzai also have similar practices. We can see that the current Pianzai is in a state of a very much state of institutional investors. On the one hand, on the one hand, on the one hand, on the one hand, Some of the major shareholders of Pianzi have reduced their holdings to a certain extent, but on the other hand, we see some well -known institutional investors, such as Gram's China -Europe Medical Hybrid Fund, which is also a large -scale blessing of Pianzai, so Pianzi 癀 is now The state is actually a relatively special state that both sides are interweaving. The game of Pianzai is actually increasing, so for the current Pianzai, there may be a relatively large problem.

Third, from the perspective of long -term market development, the overall operating status of Pianzai is actually good, in a relatively good state, so for the current Pianzi, what the most need to do is actually to establish the most important thing After all, investors' confidence, as an old Chinese medicine company, the overall performance of Pianzai is relatively stable, and it is difficult to have large -scale performance growth. Since there is no way to develop large -scale performance growth, there will be more or less problems. This may be something that the current Pianzi must consider. How can it be in the current market in suspicion, it really finds a path that suits themselves in the market and allows the market What you need to do in front of Pianzi.

- END -